国家医保局就《参照药预沟通办法（试行）》（征求意见稿）公开征求意见

Core Viewpoint - The National Healthcare Security Administration (NHSA) is seeking public opinion on the draft of the "Reference Drug Communication Method (Trial)" to enhance the scientific, fair, and standardized selection of reference drugs during the adjustment of the medical insurance drug list [1] Group 1: Policy Changes - The NHSA has introduced the practice of selecting reference drugs during the adjustment of the medical insurance drug list, which serves as an important anchor for calculating drug reimbursement standards [1] - A separate communication phase for reference drugs will be established to allow experts to propose suggestions before the adjustment process begins, thereby improving the selection process [1] Group 2: Support for Innovative Drugs - The reference drug communication work will initially focus on Class 1 new drugs, which include newly registered Class 1 chemical drugs, Class 1 therapeutic biological products, and Class 1 traditional Chinese medicines [1] - Class 1 new drugs that have not yet been approved for market but have had their applications accepted and passed technical review by the National Medical Products Administration can also apply in advance [1]